Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma.
Parastoo Bahrami DahiHillard M LazarusCraig S SauterSergio A GiraltPublished in: Bone marrow transplantation (2018)
High-dose chemotherapy and autologous hematopoietic cell transplantation (HDT-AHCT) remains an effective therapy in lymphoma. Over the past several decades, HDT with BEAM (carmustine, etoposide, cytarabine, and melphalan) and CBV (cyclophosphamide, carmustine, and etoposide) have been the most frequently used preparatory regimens for AHCT in Hodgkin (HL) and non-Hodgkin lymphoma (NHL). This article reviews alternative combination conditioning regimens, as well as novel transplant strategies that have been developed, to reduce transplant-related toxicity while maintaining or improving efficacy. These data demonstrate that incorporation of maintenance therapy posttransplant might be the best way to improve outcomes.
Keyphrases
- high dose
- cell therapy
- low dose
- stem cell transplantation
- bone marrow
- diffuse large b cell lymphoma
- oxidative stress
- single cell
- platelet rich plasma
- stem cells
- type diabetes
- mesenchymal stem cells
- big data
- randomized controlled trial
- metabolic syndrome
- machine learning
- locally advanced
- hodgkin lymphoma
- insulin resistance
- meta analyses